Gemini Therapeutics
http://geminitherapeutics.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Gemini Therapeutics
Venture Funding Deals: From ADC To Y-mAbs, Capital Flows For New Platforms, Novel Approaches
October was an active fundraising month for both start-up biopharma companies and more established privately held firms, ranging from $3m for Appili's drug for anaerobic infections to $270m for Harmony's rare disease programs.
Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m
Start-up Impact's new structured financing – its second fundraising event this month – will pay out in increments as fedratinib nears the market. Also, Ablynx closed its $200m US IPO; Chi-Med follow-on brings in $262m; and VCs gives Cydan $34m to launch new companies.
Company Information
- Industry
- Biotechnology
- Diversified
- Pharmaceuticals
-
Pharmaceuticals
- Chiral Chemistry
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Liposomes
- Nanotechnology, Chips, etc.
- Pharmacogenetics-Pharmacogenomics
- Synthesis Technologies, Production Processes
- Transgenics
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
- Molecular Diversity
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gemini Therapeutics
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice